glp 1 pediatric GLP-1 receptor agonists in obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety Use of injectable GLP-1 weight-loss

Pundole X, Jones AL, Tetzlaff MT, Williams MD, Murphy WA, Otun A, Goepfert RP, Davies MA

Although consensus was not consistently achieved regarding the prioritisation of BMI when choosing between SGLT2is and GLP-1 RAs, BMI was still recognised as one of the clinical factors that influences decision-making

Degraded peptide looks the same but works less

Three propensity-matched studies were conducted comparing each of the three drug classes

These medications rarely cause dangerously low blood sugar (hypoglycemia) on their own

Differences between GLP-1 receptor agonists and DPP-4 inhibitors[1] Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM)